CXCL12 and hepatocellular carcinoma: In a previous phase II study of sunitinib in hepatocellular carcinoma it was found that elevated plasma levels of SDF-1 were associated with poorer outcome; [29] moreover treatment with BEV of hepatocellular carcinoma determines a decrease of both VEGF and SDF-1 levels [30].